Overview

Ulipristal Acetate in Symptomatic Uterine Fibroid

Status:
Terminated

Trial end date:
2020-04-01

Target enrollment:

Participant gender:

Summary

This study evaluates the effectiveness and safety of ulipristal acetae (UPA) in women with symptomatic uterine fibroids. Those who fulfilled inclusion/exclusion criteria will be treated UPA at daily dose of 5mg.

Phase:

Phase 4

Details

Lead Sponsor:

Mỹ Đức Hospital

Collaborator:

HOPE Research Center, Ho Chi Minh City, Viet Nam

Treatments:

Ulipristal acetate